Apricus Biosciences, Inc., a biopharmaceutical company, focuses on the development of product candidates in the areas of urology and rheumatology. The company develops Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction; and RayVa, which is in Phase IIa clinical trial to treat Raynaud's phenomenon associated with scleroderma. It has a license and stock issuance agreement with Forendo Pharma Ltd. to develop and commercialize fispemifene, a tissue-specific selective estrogen receptor modulator to treat symptomatic secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms in men. Apricus Biosciences, Inc. operates in Europe, Canada, Latin America, and the Asia Pacific. The company was formerly known as NexMed, Inc. and changed its name to Apricus Biosciences, Inc. in September 2010. Apricus Biosciences, Inc. was founded in 1987 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-222-8041
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.76 million
Profitability
Miscellaneous
Employees11
OptionableNot Optionable
Apricus Biosciences (NASDAQ:APRI) Frequently Asked Questions
What is Apricus Biosciences' stock symbol?
Apricus Biosciences trades on the NASDAQ under the ticker symbol "APRI."
How were Apricus Biosciences' earnings last quarter?
Apricus Biosciences Inc (NASDAQ:APRI) issued its quarterly earnings data on Wednesday, October, 31st. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.02. View Apricus Biosciences' Earnings History.
When is Apricus Biosciences' next earnings date?
What price target have analysts set for APRI?
1 brokerages have issued 1-year price objectives for Apricus Biosciences' stock. Their forecasts range from $1.00 to $1.00. On average, they anticipate Apricus Biosciences' share price to reach $1.00 in the next twelve months. This suggests that the stock has a possible downside of 72.8%. View Analyst Price Targets for Apricus Biosciences.
What is the consensus analysts' recommendation for Apricus Biosciences?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apricus Biosciences in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Apricus Biosciences.
Has Apricus Biosciences been receiving favorable news coverage?
News stories about APRI stock have trended somewhat negative this week, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Apricus Biosciences earned a news impact score of -1.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days.
Are investors shorting Apricus Biosciences?
Apricus Biosciences saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 1,699,355 shares, an increase of 32.3% from the December 31st total of 1,284,661 shares. Based on an average daily volume of 682,913 shares, the days-to-cover ratio is currently 2.5 days. Approximately 6.2% of the company's stock are sold short. View Apricus Biosciences' Current Options Chain.
Who are some of Apricus Biosciences' key competitors?
Some companies that are related to Apricus Biosciences include Five Prime Therapeutics (FPRX), Osmotica Pharmaceuticals (OSMT), Beyondspring (BYSI), Rigel Pharmaceuticals (RIGL), OvaScience (OVAS), TG Therapeutics (TGTX), Kezar Life Sciences (KZR), Akebia Therapeutics (AKBA), Lannett (LCI), ArQule (ARQL), ZIOPHARM Oncology (ZIOP), Insys Therapeutics (INSY), Kindred Biosciences (KIN), Sinovac Biotech (SVA) and NuCana (NCNA).
Who are Apricus Biosciences' key executives?
Apricus Biosciences' management team includes the folowing people:
- Mr. Richard W. Pascoe, CEO, CFO, Sec., Principal Accounting Officer & Director (Age 55)
- Mr. Neil C. Morton, Sr. VP & Chief Bus. Officer (Age 43)
- Mr. Brian T. Dorsey, Consultant (Age 50)
- Ms. Kelly Deck, Exec. Director of Fin.
- Ms. Mary Naggs, VP & Gen. Counsel
How do I buy shares of Apricus Biosciences?
Shares of APRI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Apricus Biosciences' stock price today?
One share of APRI stock can currently be purchased for approximately $3.67.
How big of a company is Apricus Biosciences?
Apricus Biosciences has a market capitalization of $103.38 million and generates $5.76 million in revenue each year. The company earns $320,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. Apricus Biosciences employs 11 workers across the globe.
What is Apricus Biosciences' official website?
How can I contact Apricus Biosciences?
Apricus Biosciences' mailing address is 11975 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The company can be reached via phone at 858-222-8041 or via email at [email protected]
MarketBeat Community Rating for Apricus Biosciences (NASDAQ APRI)
MarketBeat's community ratings are surveys of what our community members think about Apricus Biosciences and other stocks. Vote "Outperform" if you believe APRI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APRI will underperform the S&P 500 over the long term. You may vote once every thirty days.
